Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions

被引:23
作者
Thompson, Kimberly M. [1 ,2 ]
Odahowski, Cassie L. [1 ]
机构
[1] Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA
[2] Univ Cent Florida, Coll Med, Orlando, FL 32827 USA
关键词
Benefit; cost; economic analysis; measles; rubella; COST-BENEFIT-ANALYSIS; OUTBREAK RESPONSE IMMUNIZATION; UNITED-STATES; CARE WORKERS; SUPPLEMENTARY IMMUNIZATION; VACCINATION STRATEGIES; GLOBAL ERADICATION; HOSPITAL EMPLOYEES; RADIAL HEMOLYSIS; SOUTH-AFRICA;
D O I
10.1111/risa.12331
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Economic analyses for vaccine-preventable diseases provide important insights about the value of prevention. We reviewed the literature to identify all of the peer-reviewed, published economic analyses of interventions related to measles and rubella immunization options to assess the different types of analyses performed and characterize key insights. We searched PubMed, the Science Citation Index, and references from relevant articles for studies in English and found 67 analyses that reported primary data and quantitative estimates of benefit-cost or cost-effectiveness analyses for measles and/or rubella immunization interventions. We removed studies that we characterized as cost-minimization analyses from this sample because they generally provide insights that focused on more optimal strategies to achieve the same health outcome. The 67 analyses we included demonstrate the large economic benefits associated with preventing measles and rubella infections using vaccines and the benefit of combining measles and rubella antigens into a formulation that saves the costs associated with injecting the vaccines separately. Despite the importance of population immunity and dynamic viral transmission, most of the analyses used static models to estimate cases prevented and characterize benefits, although the use of dynamic models continues to increase. Many of the analyses focused on characterizing the most significant adverse outcomes (e.g., mortality for measles, congenital rubella syndrome for rubella) and/or only direct costs, and the most complete analyses present data from high-income countries.
引用
收藏
页码:1297 / 1314
页数:18
相关论文
共 151 条
[1]   Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis [J].
Acharya, A ;
Diaz-Ortega, JL ;
Tambini, G ;
Quadros, C ;
Arita, I .
VACCINE, 2002, 20 (27-28) :3332-3341
[2]   Costs of congenital rubella syndrome (CRS) in Oman: Evidence based on long-term follow-up of 43 children [J].
Al-Awaidy, Salah ;
Griffiths, Ulla K. ;
Nwar, Hosammudin Mohammed ;
Bawikar, Shyam ;
Al-Aisiri, Masoud Salim ;
Khandekar, Rajiv ;
Mohammad, Ali Jaffer ;
Robertson, Susan E. .
VACCINE, 2006, 24 (40-41) :6437-6445
[3]  
ALBRITTON RB, 1978, POLICY ANAL, V4, P1
[4]  
Alp Emine, 2012, J Infect Public Health, V5, P127, DOI 10.1016/j.jiph.2011.11.003
[5]   WHO PAYS FOR MEASLES - THE ECONOMIC ARGUMENTS FOR SUSTAINED IMMUNIZATION [J].
ANDERSSON, N ;
PAREDES, S ;
LEGORRETA, J ;
LEDOGAR, RJ .
HEALTH POLICY AND PLANNING, 1992, 7 (04) :352-363
[6]  
[Anonymous], 1994, COST BENEFIT ANAL ME
[7]   BENEFITS DUE TO IMMUNIZATION AGAINST MEASLES [J].
AXNICK, NW ;
SHAVELL, SM ;
WITTE, JJ .
PUBLIC HEALTH REPORTS, 1969, 84 (08) :673-&
[8]   Health economics of rubella: a systematic review to assess the value of rubella vaccination [J].
Babigumira, Joseph B. ;
Morgan, Ian ;
Levin, Ann .
BMC PUBLIC HEALTH, 2013, 13
[9]   Assessing the Cost-Effectiveness of Measles Elimination in Uganda: Local Impact of a Global Eradication Program [J].
Babigumira, Joseph B. ;
Levin, Ann ;
Burgess, Colleen ;
Garrison, Louis P., Jr. ;
Bauch, Chris T. ;
Braka, Fiona ;
Mbabazi, William B. ;
Nabyonga, Juliet O. ;
Simons, Emily ;
Dabbagh, Alya .
JOURNAL OF INFECTIOUS DISEASES, 2011, 204 :S116-S123
[10]   Economic analysis of measles elimination program in the Republic of Korea, 2001: A cost benefit analysis study [J].
Bae, Geun-Ryang ;
Choe, Young June ;
Go, Un Yeong ;
Kim, Yong-Ik ;
Lee, Jong-Koo .
VACCINE, 2013, 31 (24) :2661-2666